Nuvectis Pharma has transformed from a single-drug oncology company into a rare-disease player by licensing worldwide rights (outside China) to NXP100, an oral therapy for paroxysmal nocturnal hemoglobinuria (PNH), and NXP200, an oncology asset, from Haisco Pharmaceutical Group. NXP100 showed strong Phase 3 results, outperforming the standard infused drug eculizumab with a 59.5% transfusion-free normal hemoglobin response versus 8.3%. Regulatory approval decisions in China are expected within 6 to 12 months, targeting late 2026 or early 2027. This move positions Nuvectis in a fast-growing market, with the global PNH treatment market projected to nearly double by 2030, and adds multiple near-term catalysts including upcoming oncology data and regulatory reviews.
Clearfield cut its FY2026 guidance because of delays in broadband projects linked to slow government BEAD program rollout and fiber supply constraints. However, the company secured a $22 million order for hyperscale data centers, validating its growt...
Charles Schwab is expanding its Schwab Crypto platform by adding Solana, Avalanche, and Chainlink to its existing Bitcoin and Ethereum offerings. This move aims to provide investors with more options to build diverse digital asset portfolios while le...
Bitcoin traded near $79,771 after reaching an intraday high of $81,280 but failed to break decisively above the $82,000 resistance level. Veteran trader Peter Brandt disclosed a long Bitcoin position following a bullish inverse head-and-shoulders bre...
The HYPE token reached a new all-time high of $84.80 after a 40% weekly gain and breaking the $77 resistance. Hyperliquid Strategies increased its holdings to 29.3 million HYPE tokens following a $646.6 million capital raise. The company activated an...
Xiaomi will invest $29 billion in research and development between 2026 and 2030, prioritizing advancements in custom artificial intelligence, chips, and operating systems. This investment aims to strengthen its Human x Car x Home ecosystem and boost...
